Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBSMA Ophthalmic Prostaglandins Update | OpenPaye…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MassachusettsPolicy 346

    Ophthalmic Prostaglandins

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 346 alerts

    Get alerted when Policy 346 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step-therapy coverage for ophthalmic prostaglandins under BCBSMA commercial prescription drug plans. It applies to participating Commercial members with BCBSMA formularies, including HMO/POS, PPO/EPO, Indemnity, MEDEX with Rx, and Managed Blue for Seniors, but not Medicare Advantage.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyOphthalmic Prostaglandins
    Policy CodePolicy 346
    Change TypeAdministrative updateno material clinical or coverage changes
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateNot specified
    Key ActionSubmit documented prior use of qualifying formulary alternatives for step 2 or step 3 products.
    SourceLink
    POLICY UPDATE CHANGES

    Rescula was removed from the policy because it was removed from the market.

    The 2026 annual review updated policy formatting and references without changing the criteria.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Step-therapy levels
    24 monthsLength of approval
    130 daysPrior-use lookback period
    RxApplicable benefit
    CommercialApplicable line of business

    Coverage Criteria

    Initial step-therapy coverage

    Covered according to the applicable formulary step and prior-use requirement.

    Step 1: The requested product is bimatoprost, latanoprost, tafluprost, or travoprost and is covered with no stated step requirement.

    Formulary status: Covered.

    Step 2: The requested product is Lumigan (bimatoprost), Travatan Z (travoprost), or Xalatan (latanoprost), and the member has qualifying prior use of step-therapy medication as required by the plan, including the applicable 130-day lookback.Prior use within the previous 130 days when applicable

    Formulary status: ST.

    Step 3: The requested product is Rocklatan, Xelpros, Vyzulta, or Zioptan and the member has qualifying prior use of two step 2 medications or qualifying prior use under the plan's prior-use criteria.Prior use within the previous 130 days when applicable

    Formulary status: NFNC, ST.

    Individual consideration for atypical patients

    An exception may be considered when standard criteria are not clinically appropriate.

    Individual consideration: The provider requests an exception based on unique clinical circumstances and submits supporting documentation explaining why the standard coverage criteria are unlikely to be clinically effective or may cause harm.

    For non-covered medications, the member must also have treatment failure with or a contraindication to at least two covered formulary alternatives when available.

    This policy does not apply to Medicare Advantage members.

    Requests based exclusively on the use of samples do not meet the coverage criteria for an exception. The requesting prescriber must submit additional clinical information demonstrating medical necessity for the requested medication.

    Provider Actions and Documentation

    Step Therapy

    Step-Therapy Authorization

    Submit a formulary exception/prior authorization request through Pharmacy Operations for products requiring step therapy. Document the member’s prior use of the required lower-step product(s), including product name, strength, dates when available, and treatment outcome; clinical reasons preventing a trial or switch must also be supported.

    • Requests may be submitted by phone, fax, or mail to Blue Cross Blue Shield of Massachusetts Pharmacy Operations: 1-800-366-7778; fax 1-800-583-6289; 25 Technology Place, Hingham, MA 02043.
    • The plan may use prescription claims to verify prior use within the previous 130 days and trial or failure of formulary alternatives.
    • Approval length, when granted, is 24 months.
    Step Therapy

    Three-Step Ophthalmic Prostaglandin Pathway

    For ophthalmic prostaglandins, establish the required progression through the three-step pathway before requesting a higher-step product. Provide claims history or provider documentation showing the applicable prior use and any required treatment failure.

    • Step 1 — covered formulary options: bimatoprost, latanoprost, tafluprost, and travoprost; bimatoprost is identified as covered with no requirements.

    Policy Background

    This policy addresses coverage for ophthalmic prostaglandin products under the applicable commercial prescription drug benefit. Coverage is determined primarily by formulary status and documented prior use or failure of alternative ophthalmic prostaglandins. The source does not identify a specific diagnosis or clinical indication.

    Key Definitions

    Individual consideration
    DefinitionAn exception request may be made when the coverage criteria are unlikely to be clinically effective for the prescribed purpose because of the individual’s unique clinical circumstances.
    Relevant circumstancesExamples include therapeutic contraindications, a history of adverse effects, expected ineffectiveness, or a likelihood of physical, mental, or other harm.
    Supporting documentationSubmit clinical notes or supporting statements explaining why the standard criteria are inappropriate; clinical literature, recognized drug compendia, and nationally sanctioned guidelines may also support the request.
    Non-covered medicationsWhen available, coverage of a non-covered medication also requires previous treatment failure with, or a contraindication to, at least two covered formulary alternatives.

    Initial Therapy

    Initial formulary step therapy

    Formulary step requirements for ophthalmic prostaglandins:

    Step 1: Bimatoprost, latanoprost, tafluprost, and travoprost are covered with no stated requirements.

    Covered formulary status.

    Step 2: Lumigan, Travatan Z, and Xalatan have step-therapy status and require qualifying prior use of step-therapy medication, including the applicable 130-day prior-use period.Previous 130 days when applicable

    See prior-use criteria for claims-based verification.

    Step 3: Rocklatan, Xelpros, Vyzulta, and Zioptan have NFNC/ST status and require prior use of two step 2 medications or qualifying prior use under the plan's prior-use criteria.Previous 130 days when applicable

    Continuation Therapy

    Length of approval

    Approval duration: Approved coverage is authorized for 24 months.24 months

    The document does not state additional continuation criteria.

    Step Therapy Product Pathway

    ProductFormulary statusStep requirement
    BimatoprostCoveredCovered with no requirements.
    LatanoprostCoveredCovered with no requirements.
    TafluprostCoveredCovered with no requirements.
    TravoprostCoveredCovered with no requirements.
    ProductFormulary statusStep requirement
    Lumigan (bimatoprost)STRequires qualifying prior use of step-therapy medication, including the applicable 130-day prior-use period.
    Travatan Z (travoprost)STRequires qualifying prior use of step-therapy medication, including the applicable 130-day prior-use period.
    Xalatan (latanoprost)STRequires qualifying prior use of step-therapy medication, including the applicable 130-day prior-use period.
    ProductFormulary statusStep requirement
    RocklatanNFNC, STRequires prior use of two step 2 medications or qualifying prior use under the plan's prior-use criteria, including the applicable 130-day lookback.
    XelprosNFNC, STRequires prior use of two step 2 medications or qualifying prior use under the plan's prior-use criteria, including the applicable 130-day lookback.
    VyzultaNFNC, STRequires prior use of two step 2 medications or qualifying prior use under the plan's prior-use criteria, including the applicable 130-day lookback.
    ZioptanNFNC, STRequires prior use of two step 2 medications or qualifying prior use under the plan's prior-use criteria, including the applicable 130-day lookback.
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyOphthalmic Prostaglandins
    Policy CodePolicy 346
    Change TypeAdministrative updateno material clinical or coverage changes
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateNot specified
    Key ActionSubmit documented prior use of qualifying formulary alternatives for step 2 or step 3 products.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationPolicy BackgroundKey DefinitionsInitial TherapyContinuation TherapyStep Therapy Product Pathway
  1. Step 2 — step-therapy products: Lumigan (bimatoprost), Travatan Z (travoprost), and Xalatan (latanoprost). These require prior use of a Step 1 medication or applicable prior use of a Step 2 medication; Xalatan specifies use of a Step 2 medication within the previous 130 days.
  2. Step 3 — non-formulary/non-covered step-therapy products: Rocklatan (latanoprost/netarsudil), Xelpros (latanoprost), Vyzulta (latanoprostene bunod), and Zioptan (tafluprost). These generally require prior use of two Step 2 medications or qualifying history of prior use of a Step 3 medication; Zioptan is subject to the detailed prior-use criteria.
  3. Documentation Required

    Document Formulary Alternative History

    When requesting a non-preferred product because formulary alternatives were tried and failed, identify each alternative and provide enough detail for the plan to verify the treatment history.

    • List the name and strength of every formulary alternative tried.
    • Include treatment dates when available.
    • Describe the specific treatment failure for each alternative, including the clinical response or reason the therapy was unsuccessful.
    • Document the specific clinical reason that prevents switching to or trying a formulary alternative.
    Documentation Required

    Claims or Fill History Unavailable

    Claims records may establish prior use or trial and failure, but additional provider documentation is required when prescription claims are unavailable or the fill history does not establish the applicable step-therapy criteria.

    • Provide medication names, strengths, dates, and treatment outcomes from the medical record or pharmacy history.
    • Explain whether the member used the required product(s), the duration or timing of use, and why therapy was discontinued or failed.
    • Include clinical documentation supporting any contraindication or reason a required alternative could not be tried.
    Documentation Required

    Support Individual Consideration Requests

    For an atypical patient whose clinical circumstances make the stated criteria unlikely to be effective or safe, request individual consideration and explain why an exception is medically necessary.

    • Include clinical notes or a supporting clinical statement describing the patient-specific circumstances.
    • Document therapeutic contraindications, prior adverse effects, or why the requested medication is expected to be ineffective or likely to cause harm.
    • When relevant, submit peer-reviewed literature, recognized drug-compendia references, or consensus and nationally sanctioned guideline references.
    • Submit clinical information to Pharmacy Operations by phone, fax, or mail: 1-800-366-7778; fax 1-800-583-6289; 25 Technology Place, Hingham, MA 02043.
    Denial Risk

    Required Step Therapy Not Established

    A request for a higher-step ophthalmic prostaglandin may be denied when the required prior use of lower-step therapy is not established. Do not rely solely on an unsupported statement of prior use; provide claims history or detailed provider documentation.

    • Establish the applicable Step 1 requirement before requesting a Step 2 product.
    • Establish prior use of the required Step 2 products before requesting a Step 3 product.
    • For prior-use requirements tied to the previous 130 days, provide evidence that the use occurred within that period when claims history does not confirm it.
    Denial Risk

    Exception Documentation Must Establish Medical Necessity

    An exception request may be denied when the submission does not demonstrate why the requested medication is medically necessary or why covered alternatives cannot be used. Include patient-specific clinical evidence rather than relying on a general preference for the requested product.

    • Describe the diagnosis, clinical circumstances, and requested medication’s expected benefit.
    • Provide the names, strengths, dates, and specific failure details for alternatives tried, or document the contraindication or clinical reason they cannot be tried.
    • Include relevant clinical notes, supporting statements, and appropriate peer-reviewed, compendia, consensus, or guideline evidence.
    • Requests based exclusively on use of samples do not meet exception criteria; submit additional clinical information demonstrating medical necessity.
    Prior Authorization

    Non-Covered Drug Exception Requirements

    For a non-covered medication, satisfy the individual-consideration requirements in addition to the applicable prior authorization and step-therapy criteria. The member must have treatment failure with, or a contraindication to, at least two covered formulary alternatives when available.

    • Document treatment failure with at least two covered formulary alternatives, including the product name, strength, dates when available, and specific failure details; or document a contraindication to at least two covered alternatives.
    • A higher non-preferred cost share may apply if an exception is approved for a non-preferred or non-formulary/non-covered drug.
    • Submit the Massachusetts Standard Form for Medication Prior Authorization Requests or the applicable electronic form with supporting clinical documentation.

    Additional documentation may be required if claims history does not establish prior use.